Dr David Cutter
Clinical Research Fellow (CTSU) and Consultant Clinical Oncologist (Oxford Cancer Centre)
David Cutter studied medicine at the University of Cambridge (1994-2000) and trained in Oncology at the Oxford Cancer Centre. In 2008 he joined CTSU to study for a DPhil on the late cardiovascular effects of cancer treatments. In 2013 he was appointed as a Consultant Clinical Oncologist and continues to work within CTSU upon a programme of work investigating the benefits and risks of cancer treatments.
Risk stratification of childhood cancer survivors necessary for evidence-based clinical long-term follow-up.
Frobisher C. et al, (2017), Br J Cancer, 117, 1723 - 1731
Evidence-based Review on the Use of Proton Therapy in Lymphoma From the Particle Therapy Cooperative Group (PTCOG) Lymphoma Subcommittee.
Tseng YD. et al, (2017), Int J Radiat Oncol Biol Phys, 99, 825 - 842
Predicted Cardiac and Second Cancer Risks in Hodgkin Lymphoma Patients Treated With Advanced Proton Beam Therapy Compared to Photon Radiation Therapy
Ntentas G. et al, (2017), INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS, 99, S181 - S181
Cardiac Radiation Dose Reconstruction in the Study of Late Effects: A Comparison of Different Methods
Ntentas G. et al, (2017), INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS, 99, E635 - E635
Long-term hospitalisation rates among 5-year survivors of Hodgkin lymphoma in adolescence or young adulthood: A nationwide cohort study.
Rugbjerg K. et al, (2017), Int J Cancer, 140, 2232 - 2245